APOE3xARTE10 & APOE4xARTE10 APP/PS1 Alzheimer's Models. Rensselaer, N.Y. - August 3, 2026 - Taconic Biosciences, Inc., a global leader in genetically engineered rodent models and preclinical research solutions, today announced the launch of two new Alzheimer's disease (AD) mouse models that combine the well-established APP/PS1 (ARTE10) amyloid pathology model with human APOE3 and APOE4 genetic backgrounds. Together, these models provide researchers with complementary tools to investigate both familial and sporadic aspects of Alzheimer's disease biology. Alzheimer's disease remains one of the most complex neurodegenerative disorders, with multiple genetic and pathological mechanisms contributing to disease onset and progression. While many preclinical models focus on a single disease pathway, researchers increasingly rely on multiple models to better understand disease biology and evaluate potential therapeutics. The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models address this need by combining robust amyloid pathology with clinically relevant human apolipoprotein E (APOE) genetics. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's disease, while APOE3 represents the most common human isoform and serves as an important experimental control. "Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question," said Sarah Sterlace, PhD, Senior Director, Neurobiology, Portfolio Management at Taconic Biosciences. "By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology." The complementary models enable researchers to: * Compare therapeutic responses across different human APOE genotypes. * Investigate interactions between amyloid pathology and genetic risk factors. * De-risk potential therapeutics by using models that reflect both familial and sporadic Alzheimer's disease biology. * Strengthen confidence in preclinical findings through comparative study designs. APOExAPP/PS1 (ARTE10) Platform Evaluate amyloid pathology, plaque-associated glial response, and APOE genotype effects using APOE3xARTE10 and APOE4xARTE10 human APOE APP/PS1 Alzheimer's disease models. The new models further expand Taconic's growing neurobiology portfolio, providing researchers with access to a broad range of genetically engineered models supporting Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders. "Our goal is to provide researchers with translationally relevant models aged appropriately for experimental-readiness, to answer increasingly complex scientific questions," added Sterlace. "These new additions strengthen our Alzheimer's disease portfolio and reinforce Taconic's commitment to supporting translational neuroscience research." The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models will be available for research use beginning August 21, 2026. "Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question. By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology." Sarah Sterlace, PhD, Senior Director, Neurobiology Portfolio Management, Taconic Biosciences About Taconic Biosciences Taconic Biosciences is a global leader in genetically engineered rodent models and associated services, providing innovative research models and scientific expertise to accelerate drug discovery. For more than 70 years, Taconic has partnered with pharmaceutical and biotechnology companies, academic institutions, and government organizations worldwide to advance biomedical research through industry-leading animal models, custom model generation, breeding, colony management, and scientific services. Media Contact: Travis LaFavor Director, Marketing Operations, Taconic Biosciences [email protected]

Taconic biosciences introduces new eTACONIC(R) Customer Portal. A Smarter, More Powerful Way to Manage Your Taconic Projects Taconic is excited to announce the launch of the new eTACONIC(R) Customer Portal, a modern platform designed to provide faster access to project information, enhanced visibility into your programs, and a more streamlined user experience. Built on a new technology foundation, the portal replaces the previous eTACONIC(R) platform and enables ongoing innovation, improved functionality, and future expansion across additional areas of its services and portfolio. The new platform represents a significant investment in delivering greater transparency, efficiency, and value to its customers. What is the new eTACONIC(R) portal? The new eTACONIC(R) portal is your centralized destination for monitoring project activity, reviewing inventory and shipments, accessing project documentation, and staying informed about the latest updates related to your work with Taconic. The platform has been redesigned to provide a more intuitive experience while introducing new capabilities that make it easier to find, organize, and download the information you need.